Ritu Baral

Cowen Raises Sage Value On New Phase 2 Trial Success

Sarepta's Beat And Raise Streak Continues

Cowen Analyst Responds Following Amicus' Positive Migalastat News

Sarepta's Beat And Raise Streak Continues

Cowen Analyst Responds Following Amicus' Positive Migalastat News

Payor Re-Evaluation On Exondys Positive For Sarepta

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform

Payor Re-Evaluation On Exondys Positive For Sarepta

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform

GlycoMimetics Initiated At Outperform By Cowen And Company

Audentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company

Ritu Baral Recent News

Cowen Lifts Intercept's Price Target To $215 Following Ocaliva Approval

Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review

Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?

Cowen Says PTC Therapeutics Is A Buy

Cowen And Company Analyst Explains Why Intercept Pharmaceuticals Is 'Absolutely A Buy'

Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical

UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks Continue

UPDATE: Canaccord Reiterates On Synergy Pharmaceuticals On Unmet Potential Of Plecanatide

UPDATE: Canaccord Genuity Initiates Coverage on Mast Therapeutics on MST-188 Potential

UPDATE: Canaccord Genuity Initiates Coverage on Regado Biosciences on Strong REG1 Potential

Avanir Shares Rebound As Analysts Offer Defense On Heels of 13% Drop

UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure

UPDATE: Canaccord Genuity Downgrades Optimer Pharmaceuticals Following Merger Proposal

Canaccord Genuity Reiterates Buy on Cytokinetics on CK357 Potential